قالب وردپرس درنا توس
Home / Health / Cancer discovery may help revitalize non-toxic treatment

Cancer discovery may help revitalize non-toxic treatment



Researchers from the University of Virginia published a new study on Monday that can revitalize once promising therapies that help cure solid cancer tumors. The study successfully shed light on why it targets ovarian cancer, colon cancer, and triple-negative breast cancer. The cause of immunotherapy Cancer succeeded in laboratory tests but failed in human trials. Jogender Tushir-Singh, the principal researcher of the Department of Biochemistry and Molecular Genetics of the UVA School of Medicine, pointed out that the new findings can help laboratory models achieve new success and re-run human trials. So far, researchers and protein engineers around the world, including our research team, have devoted themselves to studying supercharged and superactivated antibodies against tumor cell death receptors to fight cancer. “Tushir-Singh said, “At UVA, we have adopted a comprehensive approach to use the function of the immune system to create dual-specific and potentially clinically effective tumor treatment drugs for solid tumors. “

Tushir-Singh added: “Our findings also have the potential to further improve the clinical efficacy of the current FDA-approved PD-L1
targeting antibodies in solid tumors, especially those approved for fatal triple-negative breast cancer.” Scientists first developed a method that selectively uses antibodies to target the surface of cancer cells, called death receptor 5 (DR5). In the past, this therapy has been very successful in clinical trials and can effectively reduce tumor size in animal trials. However, when this therapy reached the standards of human clinical trials, “these antibodies have never improved the survival rate of patients.” Tushir-Singh and his research team found that “the use of anti-DR5 antibodies inadvertently triggered the suppression of the human immune response. Biological processes,” the university explained in a statement, allowing cancer cells to bypass the treatment and continue to grow.

This study shared some findings that can restore the effectiveness of treatments by antagonizing biological processes. So far, the process has proven successful in shrinking tumors and improving the survival rate of experimental mice. “We hope to see these strategies in clinical trials, and we firmly believe that they have great potential in solid tumors,” said Tuhir Singh. “Our findings are extraordinary: in addition to the impact on translation, our work also explains why after more than 60 years of research, most methods of targeting apoptosis [cell death] It did not do well in clinical trials and eventually developed resistance to the therapy. “




Source link